U.S. Markets open in 8 hrs 19 mins

Oculus receives approval for oral, throat infection products in Mexico

Oculus Innovative Sciences announced a regulatory approval in Mexico for the company's new Microcyn60 Oral Care family of products intended for use as an adjunct treatment in both mouth and throat infections. The first oral care product to be launched by Oculus' Latin American partner, More Pharma, will be Microdacyn60 Bucofaringeo. The More Pharma sales team intends to target general practitioners as well as ear, nose and throat specialists in mid-2014, enlightening these healthcare professionals to the advantages of Microdacyn60 Bucofaringeo well in advance of the 2014 fall/winter cold and flu season.